TG Therapeutics Inc (TGTX)

Debt-to-capital ratio

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Long-term debt	US$ in thousands	244,429	100,118	71,135	66,788	7,716
Total stockholders’ equity	US$ in thousands	222,364	160,502	58,587	237,153	519,350
Debt-to-capital ratio		0.52	0.38	0.55	0.22	0.01

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $244,429K ÷ ($244,429K + $222,364K)
= 0.52

The debt-to-capital ratio for TG Therapeutics Inc has shown a notable increase over the period from December 31, 2020, to December 31, 2024. Starting at a relatively low level of 0.01 at the end of 2020, the ratio climbed to 0.22 by the end of 2021, indicating a higher proportion of debt in relation to the company's total capital structure.

Further, the ratio continued its upward trend, reaching 0.55 at the end of 2022, before experiencing a slight decrease to 0.38 by the end of 2023. This fluctuation suggests potential shifts in the company's debt and capital composition during this period.

By the end of 2024, the debt-to-capital ratio stood at 0.52, indicating that debt constituted more than half of the company's total capital at that point in time. This upward trajectory in the ratio reflects an increasing reliance on debt financing within TG Therapeutics Inc's capital structure, which may be a strategic decision to fund growth opportunities or operational activities.